Adrienne E. Widener
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adrienne E. Widener has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Cameron T. Manson
J. Crayton Pruitt Family Department of Biomedical Engineering University of Florida Gainesville Florida USA
2 shared publications - Edward A. Phelps
J. Crayton Pruitt Family Department of Biomedical Engineering University of Florida Gainesville Florida USA
2 shared publications - Amanda D. Grodman1 shared publication
- Andrew M. Ladd
University of Florida Diabetes Institute, University of Florida, Gainesville, FL, USA
1 shared publication - Benjamin G. Keselowsky
J. Crayton Pruitt Family Department of Biomedical Engineering University of Florida Gainesville Florida USA
1 shared publication - Christopher P. Spencer1 shared publication
Latest Publications
- 1 November 2026
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 114 (11)
Localized IDO Delivery via Granular PEG Hydrogel Enhances Therapeutic Control of Psoriasis
Enzyme therapeutics are often limited by poor stability, rapid clearance, and systemic effects that reduce therapeutic efficacy and necessitate high dosing. Enzyme‐biomaterial conjugation can address these limitations and improve outcomes by localizing therapeutics at the tissue site of intended action. In particular, indoleamine 2,3‐dioxygenase (IDO), a potent immunomodulatory enzyme, has demonstrated therapeutic effectiveness when retained locally at sites of inflammation through fusion to a carbohydrate‐binding protein. Here, we report a complementary biomaterial‐mediated delivery strategy to prolong retention time and investigate efficacy in an imiquimod‐induced model of psoriasis. IDO maintained enzyme activity after bioconjugation to polyethylene glycol maleimide (PEG‐MAL) microgels. Localized delivery of IDO‐conjugated microgels reduced psoriatic scores compared to soluble IDO or unconjugated microgels. Additionally, fibrotic capsule thickness decreased 30% in the IDO‐conjugated microgel group compared to the unconjugated microgel. These findings demonstrate the efficacy of localized IDO delivery via covalent attachment to granular hydrogels, which may serve as a platform for other immunomodulatory enzymes.
- 1 November 2026
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 114 (11)
Localized IDO Delivery via Granular PEG Hydrogel Enhances Therapeutic Control of Psoriasis
Enzyme therapeutics are often limited by poor stability, rapid clearance, and systemic effects that reduce therapeutic efficacy and necessitate high dosing. Enzyme‐biomaterial conjugation can address these limitations and improve outcomes by localizing therapeutics at the tissue site of intended action. In particular, indoleamine 2,3‐dioxygenase (IDO), a potent immunomodulatory enzyme, has demonstrated therapeutic effectiveness when retained locally at sites of inflammation through fusion to a carbohydrate‐binding protein. Here, we report a complementary biomaterial‐mediated delivery strategy to prolong retention time and investigate efficacy in an imiquimod‐induced model of psoriasis. IDO maintained enzyme activity after bioconjugation to polyethylene glycol maleimide (PEG‐MAL) microgels. Localized delivery of IDO‐conjugated microgels reduced psoriatic scores compared to soluble IDO or unconjugated microgels. Additionally, fibrotic capsule thickness decreased 30% in the IDO‐conjugated microgel group compared to the unconjugated microgel. These findings demonstrate the efficacy of localized IDO delivery via covalent attachment to granular hydrogels, which may serve as a platform for other immunomodulatory enzymes.
- Open Access
Anti-CD3 microporous annealed particle hydrogel protects stem cell derived beta cells from autoreactive T cells
Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic beta cells, leaving patients dependent on exogenous insulin and at risk of severe hypoglycemic episodes. Stem cell-derived beta-like cells (sBCs) offer a promising approach for beta cell replacement therapy, but clinical translation is limited by immune-mediated rejection, recurrent autoimmunity, and inhospitable transplantation sites. Biomaterials have been investigated to provide localized immune-isolation and immunomodulation, but foreign body responses and rapid depletion of therapeutic agents remain as obstacles to clinical translation. Here, we present a microporous annealed particle (MAP) hydrogel functionalized with an anti-CD3 monoclonal antibody (αCD3) to provide a localized immunomodulatory microenvironment for beta cell replacement therapy. MAP hydrogels consisting of guest-host interlinked polyethylene glycol-maleimide (PEG-MAL) microgels supported rapid vascularization, minimal foreign body response, and engraftment of syngeneic islets in mice. αCD3 MAP hydrogel halted T cell migration in vitro and protected transplanted sBCs from immune-mediated destruction by HLA-matched diabetogenic T cells in vivo . Subcutaneous αCD3 functionalized MAP hydrogel also protected the endogenous islets in the pancreas, demonstrating potential for systemic immune modulation. These findings establish αCD3 MAP hydrogels as a promising strategy for localized immune modulation in cell replacement therapy.
Open AccessAnti-CD3 microporous annealed particle hydrogel protects stem cell derived beta cells from autoreactive T cells
Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic beta cells, leaving patients dependent on exogenous insulin and at risk of severe hypoglycemic episodes. Stem cell-derived beta-like cells (sBCs) offer a promising approach for beta cell replacement therapy, but clinical translation is limited by immune-mediated rejection, recurrent autoimmunity, and inhospitable transplantation sites. Biomaterials have been investigated to provide localized immune-isolation and immunomodulation, but foreign body responses and rapid depletion of therapeutic agents remain as obstacles to clinical translation. Here, we present a microporous annealed particle (MAP) hydrogel functionalized with an anti-CD3 monoclonal antibody (αCD3) to provide a localized immunomodulatory microenvironment for beta cell replacement therapy. MAP hydrogels consisting of guest-host interlinked polyethylene glycol-maleimide (PEG-MAL) microgels supported rapid vascularization, minimal foreign body response, and engraftment of syngeneic islets in mice. αCD3 MAP hydrogel halted T cell migration in vitro and protected transplanted sBCs from immune-mediated destruction by HLA-matched diabetogenic T cells in vivo . Subcutaneous αCD3 functionalized MAP hydrogel also protected the endogenous islets in the pancreas, demonstrating potential for systemic immune modulation. These findings establish αCD3 MAP hydrogels as a promising strategy for localized immune modulation in cell replacement therapy.